• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

'Exciting Era' Underway

Article

San Francisco -- Patients with moderate to severe psoriasis can receive efalizumab (Anti-CD11a) continually with no increased toxicity for approximately one year, an ongoing open-label trial shows.

Related Videos
Related Content
2 Years of Treatment With Dupilumab Led to Improvements In Symptoms of AD and Comorbid Anxiety, Depression

2 Years of Treatment With Dupilumab Led to Improvements In Symptoms of AD and Comorbid Anxiety, Depression

Article
The Cutaneous Connection: A Reminder of Patient Impact

The Cutaneous Connection: A Reminder of Patient Impact

Podcast
Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 1

Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 1

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
Patients With Vitiligo Have Decreased Risk of Subsequent Pulmonary Embolism, Peripheral Vascular Disease

Patients With Vitiligo Have Decreased Risk of Subsequent Pulmonary Embolism, Peripheral Vascular Disease

Article
Striving for Melanoma Advancements With the Melanoma Research Alliance

Striving for Melanoma Advancements With the Melanoma Research Alliance

Article
© 2024 MJH Life Sciences

All rights reserved.